Chargement en cours...
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy
Hepatitis C virus (HCV) treatments have dramatically progressed from poorly tolerated, moderately successful interferon-based therapies to highly effective all-oral interferon-free regimens. While sustained virologic responses have significantly improved with fixed-dose combinations (FDC) of these d...
Enregistré dans:
| Publié dans: | Hepatol Int |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436099/ https://ncbi.nlm.nih.gov/pubmed/29845496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12072-018-9873-y |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|